Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Mobidiag, Genewave and Amplidiag Announce Definitive Agreement

Published: Monday, April 15, 2013
Last Updated: Monday, April 15, 2013
Bookmark and Share
The new Mobidiag to offer integrated, high-multiplex diagnostic tests for infectious diseases.

Mobidiag Oy/Ltd, Genewave SAS, and Amplidiag Oy have announced a definitive agreement to combine the three companies to create a technology leader in molecular diagnostics for infectious diseases.

The new Mobidiag combines Mobidiag’s and Amplidiag’s high-multiplex proprietary diagnostic test portfolios with Genewave’s automated and integrated test platform.

The merger was accompanied by a financing round by existing investors Helsinki University Fund, iXLife, Tutor Invest (Medtech Rahasto Ky), and others, as well as public funding support from the Finnish funding agencies, Tekes and Finnvera, and the EU.

Joining as Mobidiag’s new CEO is Tuomas Tenkanen, the former R&D Director of the diagnostics PCR products provider, Finnzymes Oy, which was acquired by Thermo Fisher Scientific.

The transaction was effected as a share exchange, upon which Genewave and Amplidiag became subsidiaries of Mobidiag Oy/Ltd.

The new company is headquartered in Helsinki, with a center of excellence in Paris, and now has the diagnostic test pipeline, integrated test platform, leadership, infrastructure, and financial resources to develop and bring to commercialization its automated instrument and panel of diagnostic tests, capable of identifying a large number of pathogens from a single patient sample.

“The fusion of these three complementary companies creates a unique opportunity to bring forward the next generation of infectious disease diagnostics to dramatically improve global health care,” said Tuomas Tenkanen, CEO, Mobidiag.

Genewave specializes in the development, manufacturing and marketing of cutting-edge microarray instrumentation for diagnostic, clinical and life science research.

Genewave’s innovative GeneSpress® system is an automated and integrated platform for highly multiplexed molecular diagnostic tests.

The compact system integrates DNA purification, PCR amplification and microarray hybridization and detection into an automated workflow on a single, closed lab-on-chip cartridge.

Among other innovative features, the platform incorporates Genewave’s patented TouchArray™ optical detection technology for highly sensitive imaging of microarrays.

Mobidiag’s clinically proven, CE-IVD marked Prove-it™ diagnostic tests enable up to 84 pathogens and antibiotic resistance markers to be detected in a single assay, representing cutting-edge multiplexing capabilities.

Current test products are intended for diagnosing bacterial and fungal sepsis, viral central nervous system infections and bacterial bone and joint infections. Mobidiag has built a reference customer base with its current test portfolio and has generated market acceptance in Europe.

The automation of Mobidiag’s tests will answer the need of clinical laboratories for automated and integrated solutions for diagnostic testing of severe infectious diseases.

Amplidiag provides a broad panel of diagnostic tests for infectious diseases. Amplidiag has substantial intellectual property covering testing and nucleic acid extraction methods for contagious gastrointestinal and other serious diseases.

The global molecular diagnostics market exceeds 5 billion EUR, and is growing more than 15% annually.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Mobidiag and Unilabs Enter into Agreement
The agreement solidifies Unilabs’ position as an industry-leading diagnostics service provider and is a major milestone for Mobidiag in European market entry.
Tuesday, September 01, 2015
Mobidiag Announces CE Marking of Amplidiag™ H. pylori+ClariR
Test is first-to-market, non-invasive IVD assay for reliable detection of both Helicobacter pylori and clarithromycin resistance from stool sample.
Wednesday, June 03, 2015
Scientific News
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos